10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

CLDN2 Antibody (C-term Y195) Blocking peptide

Synthetic peptide
Catalog # BP12632b

Specification

CLDN2 Antibody (C-term Y195) Blocking peptide - Product Information

Primary Accession P57739

CLDN2 Antibody (C-term Y195) Blocking peptide - Additional Information

Gene ID 9075

Other Names
Claudin-2, SP82, CLDN2

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

CLDN2 Antibody (C-term Y195) Blocking peptide - Protein Information

Name CLDN2

Function
Plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity.

Cellular Location
Cell junction, tight junction {ECO:0000250|UniProtKB:O88552}. Cell membrane {ECO:0000250|UniProtKB:O88552}; Multi-pass membrane protein {ECO:0000250|UniProtKB:O88552}

CLDN2 Antibody (C-term Y195) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

CLDN2 Antibody (C-term Y195) Blocking peptide - Images

CLDN2 Antibody (C-term Y195) Blocking peptide - Background

10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

This gene product belongs to the claudin protein familywhose members have been identified as major integral membraneproteins localized exclusively at tight junctions. Claudins areexpressed in an organ-specific manner and regulate tissue-specificphysiologic properties of tight junctions. This protein isexpressed in the intestine. Alternatively spliced transcriptvariants with different 5' untranslated region have been found forthis gene.

CLDN2 Antibody (C-term Y195) Blocking peptide - References

Smith, A.J., et al. J. Acquir. Immune Defic. Syndr. 55(3):306-315(2010)Kojima, F., et al. Oncol. Rep. 23(4):927-931(2010)Szakal, D.N., et al. Virchows Arch. 456(3):245-250(2010)Buchert, M., et al. Proc. Natl. Acad. Sci. U.S.A. 107(6):2628-2633(2010)Mankertz, J., et al. Cell Tissue Res. 336(1):67-77(2009)